EP Patent

EP3744320A1 — Pharmaceutical tablet composition comprising edoxaban

Assigned to Alfred E Tiefenbacher GmbH and Co KG · Expires 2020-12-02 · 5y expired

What this patent protects

The invention relates to a pharmaceutical composition in the form of a tablet, comprising a) edoxaban, or a salt thereof or a hydrate of said edoxaban or edoxaban salt, as an active ingredient, b) lactose as a water-soluble filler, and c) crospovidone and sodium starch glycolate …

USPTO Abstract

The invention relates to a pharmaceutical composition in the form of a tablet, comprising a) edoxaban, or a salt thereof or a hydrate of said edoxaban or edoxaban salt, as an active ingredient, b) lactose as a water-soluble filler, and c) crospovidone and sodium starch glycolate as disintegrants. The invention further relates to the pharmaceutical composition for use as a medicament in the treatment and/or prevention of a medical condition associated with unwanted blood clots, and to methods for preparing the pharmaceutical composition using wet granulation methods.

Drugs covered by this patent

Patent Metadata

Patent number
EP3744320A1
Jurisdiction
EP
Classification
Expires
2020-12-02
Drug substance claim
No
Drug product claim
No
Assignee
Alfred E Tiefenbacher GmbH and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.